Malin predicts sale or flotation of Poseida within the year

The Irish drug and biotech fund Malin has said it sees a sale or stock market listing of its flagship company Poseida within the next year.

Poseida, in which Malin owns about 25 per cent, had filed for a stock market listing earlier this year but this was postponed as it raised $142 million from investors including drug giant Novartis. Malin pumped in a further $4 million.

Darragh Lyons, Malin’s chief business and ...